Top News Chief Reporter Hao Ruiling Reporter Guo Dingran
The disclosure of the first quarterly report of A-shares ushered in the end, and all 111 A-share listed companies in Henan publicly disclosed their financial data for the first quarter of 2024.
What is the profitability of Henan stocks, the top news will take you to understand the first quarterly report of Henan A-share listed companies (the data in the article is sorted out from Flush iFind).
[CMOC won the top 1 in revenue]
Overall, in the first quarter of 2024, the total revenue of 111 Henan enterprises will reach 233.7 billion, with an average revenue of about 2.1 billion yuan, and the "28 effect" is obvious, with 21 companies having higher revenue than the average, contributing nearly 80% of the total revenue.
There are three enterprises with revenue exceeding 10 billion yuan in the first quarter, namely China Molybdenum, Muyuan Co., Ltd. and Shuanghui Development. These three companies are also the top three in terms of revenue in Henan stocks in 2023, and the revenue of CMOC and Muyuan Co., Ltd. both exceeded 100 billion yuan that year.
In the first quarter of 2024, CMOC won the crown of "Top 1 in Revenue" with a score of 46.121 billion yuan, and its revenue was 19.849 billion yuan ahead of the second place Muyuan Co., Ltd., which can be called a "fault debut".
Zhengmei Machinery, Yuguang Gold and Lead, Anyang Iron and Steel, Pingmei Shares, Shenhuo Shares, Longbai Group and Mingtai Aluminum followed closely behind and entered the top 10 list of revenue in the first quarter.
Although they are on the top 10 list in terms of revenue, the gap between the companies is obvious, taking the 10th place Mingtai Aluminum as an example, in the first quarter of 2024, its revenue is only 15.6% of CMOC.
Among the 111 companies, 69 companies achieved revenue growth, accounting for more than 6 percent, but the overall growth rate was slow.
From the perspective of individual stocks, Kaiwang Technology and Zhongcheng Technology have the highest revenue growth rate, with a year-on-year increase of 104% and 101.57% respectively. However, it should be noted that Kaiwang Technology's net profit in this quarter was a loss of 8.8985 million yuan, a year-on-year decrease of 31.75%, a net profit loss of 15.4349 million yuan, and a net cash flow from operating activities of 35.8425 million yuan, a year-on-year decrease of 354.21%.
Kaiwang Technology said that during the reporting period, the company continued to increase investment in research, production and sales, the sales price of some mature products decreased, and the continuous rise in material costs and labor costs was one of the main reasons for the decline in the company's main business net profit in the current period.
[More than eighty percent of Yu stock profits]
A total of 111 Henan enterprises achieved a net profit of 14.057 billion, of which 92 companies achieved profits, accounting for more than eighty percent of the total number of Henan stocks. 88 enterprises deducted net profit losses from non-attributable to their parents.
In the first quarter of 2024, CMOC's net profit reached 2.32 billion yuan, making it a well-deserved "double king" in terms of revenue and net profit. Shuanghui Development ranked second, with a net profit of 1.287 billion yuan. In addition, the net profit of Zhengmei Machinery, Shenhuo Co., Ltd., and COFCO Capital also exceeded 1 billion yuan.
However, a high net profit does not equate to the quality of a company's net earnings. If the net present ratio is considered, the net profit of Yuneng Holdings, Tuoxin Pharmaceutical, Sanhui Electric, Qiule Seeds, Rebecca, Jie'an Hi-Tech, China Optics, Zhongyuan Securities, and Yutong Bus may be higher.
In terms of operating profit margin, 10 companies, including Hualan Vaccine, Power Diamond, Brilliant Technology, Kaipu Testing, Thinking Train Control, Hualan Biotechnology, New Open Source, Bank of Zhengzhou, and Zhongzhi Technology, ranked ahead.
Affected by the supply and demand of the industry, Muyuan's loss in 2023 extended to the first quarter of this year, with a loss of 2.459 billion yuan during the reporting period, a year-on-year decrease of 104.81%, and a net profit loss of 2.387 billion yuan, a year-on-year decrease of 90.62%.
In addition, Anyang Iron and Steel, Dayou Energy, Yellow River Whirlwind, and Palm shares also lost more than 100 million yuan.
From the perspective of stock price performance, in the first quarter of 2024, 58 companies will have a year-on-year decline in basic earnings per share, and 7 companies will be the same as last year.
The top 10 earnings per share are Zheng Coal Machinery, Antu Biotechnology, Yituo Shares, Ruifeng New Materials, Zhongjing Food, Shenhuo Shares, Zhongyuan Environmental Protection, Longbai Group, Power Diamond and Jianlong Micro-Nano, Zheng Coal Machinery's earnings per share reached 0.59 yuan.
["Specialized, special and new" is more generous in R&D]
In addition, from the financial report, we can also see the strong R&D strength and investment determination of Henan's listed enterprises, and the R&D investment of leading enterprises has reached a new high, demonstrating the great importance attached to technological innovation and sustainable development.
In terms of R&D expenses, Muyuan Co., Ltd., Zhengmei Machinery Co., Ltd., and Mingtai Aluminum led the top three, and the R&D investment of the three companies in the first quarter exceeded 400 million yuan.
AVIC Optoelectronics and Yutong Bus both invested more than 300 million yuan in R&D, ranking fourth and fifth respectively.
On the whole, 9 of the top 10 listed companies in R&D investment in the first quarter exceeded 100 million yuan.
The R&D investment of YTO shares, which ranked tenth, also exceeded 95 million yuan in the first quarter.
According to the statistics of Flush iFind, 37.8% of the A-share Henan enterprises are "specialized, special and new" enterprises, and the importance of these enterprises to R&D can also be seen through the intensity of R&D investment.
Among the 15 enterprises with R&D investment intensity (the proportion of current R&D investment in current revenue) exceeding 10%, 12 are "specialized, special and new" enterprises.
In particular, Tianmai Technology ranked first with an investment intensity of 94.72% (revenue of 13.3218 million yuan in the first quarter and R&D investment of 12.6183 million yuan in the first quarter). Compared with the amount of R&D investment of 12.1495 million yuan in the first quarter of 2023, an increase of 3.86%.
Tianmai Technology has been rooted in the smart public transportation industry for 20 years, comprehensively opened up all links in the field of smart public transportation, established and improved the ecological system of smart public transportation construction, and can provide overall solutions for urban public transportation. It has provided services to more than 400 cities, more than 700 transportation enterprises and industry management departments, and its market share is at the forefront of the industry.
According to the data, Tianmai Technology is vigorously developing the intelligent cockpit business of commercial vehicles to promote the company's strategic transformation, enrich the company's product structure, and improve profitability.
In addition, it is worth noting that Antu Biotech's R&D investment is about 151 million, and the R&D investment intensity reaches 13.88%, ranking among the top 10 in terms of R&D investment amount and R&D investment.
According to the financial report data, in the first quarter of 2024, Antu Biotech achieved operating income of 1.089 billion yuan, a year-on-year increase of 5.09%; The net profit attributable to the parent company was 324 million yuan, a year-on-year increase of 33.93%.
On the basis of continuous R&D and high investment, Antu Biotech continues to work hard in the field of reagent R&D and has successfully developed a number of new series of products.
Previously, Antu Biotech said that in 2024, it will continue to deepen the traditional advantageous fields, and at the same time promote the upgrading from traditional infectious diseases, tumor and other testing items to emerging and leading projects such as autoimmunity and allergens.
In addition, Antu Biotech will accelerate the development of the field of precision detection and upgrade from the field of traditional diagnosis to the field of precision diagnosis. Increase R&D investment in the field of precision detection, and achieve new breakthroughs in early cancer screening, cancer companion diagnostics and other products.